Nalaganje...
Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China
BACKGROUND. Trastuzumab is a key component of therapy for human epidermal growth receptor 2 (HER2) positive breast cancer. Because real‐world data are lacking, the present research was conducted to evaluate the actual use of and the effectiveness of trastuzumab in the real world in China. METHODS. I...
Shranjeno v:
| izdano v: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AlphaMed Press
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5679829/ https://ncbi.nlm.nih.gov/pubmed/28798274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0088 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|